

CLEARBRIDGE HEALTH LIMITED

(Company Registration No.: 201001436C)

(Incorporated in the Republic of Singapore)

RECONSTITUTION OF THE BOARD AND BOARD COMMITTEES

The board of directors (the “**Board**”) of Clearbridge Health Limited (the “**Company**”) wishes to announce the appointment of Mr. Wu Yu Liang as Non-Executive and Independent Chairman of the Company and appointment of Mr. Vitters Sim Yu Xiong as Non-Executive Non-Independent Director of the Company, with effect from 1 July 2026.

The Board considers Mr. Wu Yu Liang to be independent for the purposes of Rule 704(7) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Limited (the “**Catalist Rules**”).

The detailed template announcement pursuant to Rule 704(6) of the Catalist Rules in relation to the abovementioned appointments have been separately announced on SGXNET today.

Following the abovementioned appointments, Mr. Yee Pinh Jeremy will be stepping down as member of Nominating Committees and the composition of the Board and Board Committees of the Company shall be reconstituted effective from 1 July 2026 as follows:

Board

Mr. Wu Yu Liang	Non-Executive and Independent Chairman
Mr. Ong Choon Yi (Wang Junyi)	Executive Director and Group Chief Executive Officer
Mr. Andrew John Lord	Lead Independent Director
Mr. Mark Benedict Ryan	Independent Director
Mr. Yee Pinh Jeremy	Non-Executive Non-Independent Director
Mr. Vitters Sim Yu Xiong	Non-Executive Non-Independent Director

Audit Committee

Mr. Mark Benedict Ryan	(Chairman)
Mr. Andrew John Lord	(Member)
Mr. Wu Yu Liang	(Member)

Nominating Committee

Mr. Wu Yu Liang	(Chairman)
Mr. Andrew John Lord	(Member)
Mr. Mark Benedict Ryan	(Member)

Remuneration Committee

Mr. Andrew John Lord	(Chairman)
Mr. Mark Benedict Ryan	(Member)
Mr. Wu Yu Liang	(Member)

By Order of the Board

Andrew John Lord
Lead Independent Director

1 July 2026

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the

“Sponsor”).

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.